Evaxion presents promising results on evx-b1, an ai-designed vaccine against staphylococcus aureus

Copenhagen, denmark, july 31, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the discovery and development of ai-powered immunotherapies, presents promising results of evx-b1 at the staphylococcal diseases gordon research conference in new hampshire, usa.

EVAX Ratings Summary

EVAX Quant Ranking